SynthesisRespiratory research & clinical practice2026
Safety and tolerability of linezolid to treat tuberculosis: a systematic review and meta-analysis.
Synthesis in Respiratory research & clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Linezolid in the era of bedaquiline-pretomanid-linezolid-based regimens: an indispensable challenge.Respiratory research & clinical practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: In a previous review, we summarized the safety of linezolid-containing regimens to treat rifampin-resistant/multidrug-resistant tuberculosis (RR/MDR-TB), underscoring the persistent need for shorter and safer regimens. The objective of the present study was to explore the safety and tolerability directly attributable to linezolid in regimens designed to treat RR/MDR-TB in studies published between 2009 and 2025. Methods: We searched PubMed/MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, Scopus, and Web of Science for studies reporting on the safety and tolerability of linezolid since it was introduced as a repurposed drug in the treatment of tuberculosis. Results: A total of 22 studies (including 26 arms) were identified, with a total of 3,014 patients. There was significant variation in geographic distribution, sample size (range, 8-655), linezolid dose (range, 300-1,200 mg), duration, and other core variables. The pooled rate of favorable outcomes among cohort studies (cure or treatment completion) was = 80.1%. Hematologic disorders (including anemia, thrombocytopenia, and leukopenia, in 33.1%) and peripheral neuropathy (in 33.9%) were the most common adverse events (AEs), followed by psychiatric and neurological disorders (in 12.3%), myalgia (in 7.0%), optic neuropathy (in 7.8%), gastrointestinal events (in 1.9%), ototoxicity (in 2.9%), and rash (in 1.0%). Serious AEs were rarely reported. Conclusions: Although the recommended linezolid-containing regimens are considered safe, linezolid still causes frequent and severe AEs. A new drug with similar characteristics but lower toxicity will significantly improve the safety of antituberculosis regimens, with improved adherence and treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.